Aptar launches biologics focused auto-injector

- Last updated on GMT

Related tags: Pharmacology

Aptar launches biologics focused auto-injector
Aptar launches biologics focused auto-injector
Aptar Pharma has launched a new auto-injector technology as part of a strategic effort to build its presence in the biopharmaceutical sector.

The new Pro-Ject technology – which was unveiled at the PDA Europe Conference in Basel, Switzerland earlier this month – is designed around a standard prefilled syringe and features a large control window, acoustic feedback and various safety features, included as a result of consultation with patients and physicians.

The launch is part of Aptar’s effort to grow in the biopharmaceuticals sector, which began with the strategic partnership it formed with UK-based parenteral technology firm Oval Medical​ in November 2011.

The process continued with the acquisition of French closure developer Stelmi in June last year for €165m ($205m), which was an agreement that took Aptar beyond its traditional focus on inhalers into primary packaging components for injectable delivery devices.

At the time CEO Steve Hagge told us that: “Prefillable is one of our big interests in the [Stelmi] acquisition” and combining these with assets gained with Oval would allow Aptar to grow in the biopharmaceutical sector.

The Pro-Ject technology may be one of a number of new technologies Aptar will roll out over the next few year judging by comment made by spokesman Pierre Carlotti at the launch event.

“It has been a very exciting time during the last two years preparing for this market launch. Pro-Jectis the first member of our future range of innovative injection devices.”

Pharma gains

Aptar’s sales to the drug industry played a part in gains made by the firm in Q3. Group revenue for the three months ended September 30 increased 6 percent to $624m with those from its pharma segment increasing 7 per cent.

Morningstar analyst Todd Wenning said: “While Aptar's food and beverage and beauty and home divisions are competitive, it's clear that its pharmaceutical division is the major differentiating factor between Aptar and its closest peers in the dispensing product business.​”

Related news

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Related suppliers

Follow us


View more